Copy to clipboard 
3D Systems and Theradaptive entered a commercial agreement naming 3D Systems as Theradaptive’s exclusive 3D printing partner. The companies intend to deliver a novel approach to promote bone and tissue growth using Theradaptive’s protein-based material-binding variants to coat 3D Systems’ 3D-printed medical devices.
In addition to being named as Theradaptive’s exclusive 3D printing partner, 3D Systems also made an $8 million investment in the company.
“This agreement enables an exciting technological convergence of 3D Systems’ cutting-edge advances in orthopedic and soft tissue additive manufacturing and Theradaptive’s material-binding regenerative therapeutics,” said Luis Alvarez, CEO and founder of Theradaptive. “Uniting these two world-class technologies promises to provide safer and more effective treatment options for patients who currently have few options. This partnership sets the stage for many new products that will have the potential to significantly improve patient care.”
“The combination of both companies’ expertise and experience and relentless pursuit of enabling an improved patient experience is a strong foundation for this collaboration,” said Andrew Johnson, EVP, chief corporate development officer, chief legal counsel, 3D Systems. “We believe that enhancing 3D Systems’ unparalleled capabilities in medical device design and production with the benefits of Theradaptive’s protein-engineering platform has the potential to make a significant impact on the field of regenerative medicine, and patients’ lives.”
